Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHT1AS)

• Drug Name: ANVS301 Drug Info
• Synonyms: Bisnormcerysine

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHT1AS

Molecule-Related Drug Atlas

Drug(s) Targeting Amyloid beta A4 protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[3]
Aducanumab	DM51JW4	Alzheimer disease	8A20	Approved	[4]
Lecanemab	DMW03YD	Alzheimer disease	8A20	Approved	[5]
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[6]
GV-971	DMTMA5W	Alzheimer disease	8A20	Approved in China	[7]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[9]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[10]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[11]
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Inhibitor	[2]

References

• [1] Clinical pipeline report, company report or official report of Annovis Bio
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
• [5] The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [7] Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
• [8] Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
• [9] Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
• [10] Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
• [11] Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)